CareDx Inc (CDNA), a precision medicine company developing and marketing diagnostic solutions for transplant patients, is charting an ambitious path forward, with a goal of reaching $500 million in annual revenue by 2027.
The company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey. It also provides genomics-driven insights for transplant patients in the United States, where approximately 46,000 transplants are performed annually. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a donor-derived cell-free DNA solution for heart transplant patients; and AlloSure Lung, a donor-derived cell-free DNA solution for lung transplant patients.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.